WO2002012471A3 - Homologue de l'enzyme de conversion de l'angiotensine et utilisations - Google Patents

Homologue de l'enzyme de conversion de l'angiotensine et utilisations Download PDF

Info

Publication number
WO2002012471A3
WO2002012471A3 PCT/US2001/025059 US0125059W WO0212471A3 WO 2002012471 A3 WO2002012471 A3 WO 2002012471A3 US 0125059 W US0125059 W US 0125059W WO 0212471 A3 WO0212471 A3 WO 0212471A3
Authority
WO
WIPO (PCT)
Prior art keywords
converting enzyme
angiotensin converting
uses therefor
enzyme homolog
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/025059
Other languages
English (en)
Other versions
WO2002012471A2 (fr
Inventor
Susan Acton
Keith E Robison
Frank Y Hsieh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/635,501 external-priority patent/US6884771B1/en
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to AU2001284794A priority Critical patent/AU2001284794A1/en
Publication of WO2002012471A2 publication Critical patent/WO2002012471A2/fr
Publication of WO2002012471A3 publication Critical patent/WO2002012471A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15—Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne la découverte de nouveaux gènes codant pour une enzyme de conversion de l'angiotensine, l'enzyme 2 de conversion de l'angiotensine (ACE-2). L'invention concerne également des méthodes thérapeutiques, de pronostic et de diagnostic permettant de traiter les troubles associés à la pression sanguine ainsi que divers types de conditions allergiques, entre autres. L'invention concerne en outre des analyses de criblage visant à identifier des composés permettant de traiter et de prévenir ces conditions.
PCT/US2001/025059 2000-08-09 2001-08-09 Homologue de l'enzyme de conversion de l'angiotensine et utilisations Ceased WO2002012471A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001284794A AU2001284794A1 (en) 2000-08-09 2001-08-09 Angiotensin converting enzyme homolog and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/635,501 2000-08-09
US09/635,501 US6884771B1 (en) 1997-12-11 2000-08-09 Angiotensin converting enzyme homolog and uses therefor

Publications (2)

Publication Number Publication Date
WO2002012471A2 WO2002012471A2 (fr) 2002-02-14
WO2002012471A3 true WO2002012471A3 (fr) 2003-01-03

Family

ID=24548043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025059 Ceased WO2002012471A2 (fr) 2000-08-09 2001-08-09 Homologue de l'enzyme de conversion de l'angiotensine et utilisations

Country Status (2)

Country Link
AU (1) AU2001284794A1 (fr)
WO (1) WO2002012471A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098448A1 (fr) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Procedes et compositions destines a moduler l'activite de l'enzyme de conversion d'angiotensine-2 (ace-2)
US6592865B2 (en) 2001-06-04 2003-07-15 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
DE60324925D1 (de) * 2002-06-19 2009-01-08 Univ Health Network Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
EP1570854A4 (fr) * 2002-10-29 2008-07-30 Gen Kondoh Medicament contenant une angiotensine convertase
EP1723962A1 (fr) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Utilisation des inhibiteurs du système de rénine-angiotensine pour le traitement des lesions poumonaires.
US20090186014A1 (en) * 2007-10-10 2009-07-23 Ore Pharmaceuticals Inc. Method for treatment of pancreatitis
JP2011513491A (ja) * 2008-03-10 2011-04-28 オレ・ファーマシューティカルズ・インコーポレーテッド 近位消化管の障害の治療
JP2012508588A (ja) * 2008-12-02 2012-04-12 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ２阻害剤の同定のためのスクリーニングアッセイ
EP3820498A1 (fr) * 2018-06-14 2021-05-19 University College Cork-National University of Ireland Cork Peptide pour le traitement de maladies
EP4138998A4 (fr) * 2020-04-24 2024-05-22 The Administrators of The Tulane Educational Fund Compositions et procédés visant à prévenir ou réduire les effets d'infections par des coronavirus qui se lient au domaine extracellulaire du récepteur ace2
WO2021236957A2 (fr) * 2020-05-20 2021-11-25 Emmune, Inc. Mutéines ace2 et procédés d'utilisation de celles-ci
US20240352072A1 (en) * 2021-04-20 2024-10-24 The Council Of The Queensland Institute Of Medical Research Novel compositions and methods for treating coronavirus infections
EP4147702A1 (fr) 2021-09-13 2023-03-15 Medizinische Universität Graz Nouvelle combinaison d'héparine et de leurres ace2 pour le traitement de la covid-19

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974644A1 (fr) * 1998-07-23 2000-01-26 Ajinomoto Co., Inc. Méthode pur la prodution de levure résistant à la congelation
EP0974664A2 (fr) * 1998-05-13 2000-01-26 Smithkline Beecham Plc Polypeptides et polynucleotides humains ayant une homologie avec l'enzyme de conversion de l'angiotensine spécifique des testicules
WO2000018899A2 (fr) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Homologue d'enzyme de conversion d'angiotensine et son utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974664A2 (fr) * 1998-05-13 2000-01-26 Smithkline Beecham Plc Polypeptides et polynucleotides humains ayant une homologie avec l'enzyme de conversion de l'angiotensine spécifique des testicules
EP0974644A1 (fr) * 1998-07-23 2000-01-26 Ajinomoto Co., Inc. Méthode pur la prodution de levure résistant à la congelation
WO2000018899A2 (fr) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Homologue d'enzyme de conversion d'angiotensine et son utilisation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BERNSTEIN: "Two ACEs and a heart", NATURE, vol. 417, 20 June 2002 (2002-06-20), pages 799 - 802, XP002207554 *
DATABASE EMBL [online] 1 July 2000 (2000-07-01), "Homo sapiens angiotensin converting enzyme-like protein mRNA, complete cds", XP002207559, Database accession no. AF241254 *
DATABASE GENESEQ [online] 11 April 2000 (2000-04-11), "Human MPROT15 amino acid sequence #1", XP002207557, Database accession no. AAY67310 *
DATABASE GENESEQ [online] 11 April 2000 (2000-04-11), "Human MPROT15 coding sequence", XP002207558, Database accession no. AAZ59465 *
DATABASE GENESEQ [online] 25 July 2000 (2000-07-25), "A human angiotensin converting enzyme-2 (ACE-2) protein", XP002207555, Database accession no. AAY84562 *
DATABASE GENESEQ [online] 25 July 2000 (2000-07-25), "cDNA encoding a human angiotensin converting enzyme-2 (ACE-2)", XP002207556, Database accession no. AAA12764 *
DATABASE SWALL [online] 1 October 2000 (2000-10-01), "Angiotensin converting enzyme-like protein (ACE-related carboxypeptidase ACE2)", XP002207560, Database accession no. Q9NRA7 *
DONOGHUE MARY ET AL: "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.", CIRCULATION RESEARCH, vol. 87, no. 5, 1 September 2000 (2000-09-01), pages e1 - e9, XP002207553, ISSN: 0009-7330 *
TIPNIS ET AL.: "A human homolog of Angiotensin-converting enzyme", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 43, 27 October 2000 (2000-10-27), pages 33238 - 33243, XP002207551 *

Also Published As

Publication number Publication date
WO2002012471A2 (fr) 2002-02-14
AU2001284794A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2000018899A3 (fr) Homologue d'enzyme de conversion d'angiotensine et son utilisation
WO2002012471A3 (fr) Homologue de l'enzyme de conversion de l'angiotensine et utilisations
EP0976829A3 (fr) Enzyme capable de déamider des protéines, gène codant pour celle-ci, méthode de production de cette enzyme et son utilisation
AU2003275613A1 (en) Novel fructosyl peptide oxidase and utilization thereof
WO2002062157A3 (fr) Traitement de melanges contenant des phosphatides
WO2002006534A3 (fr) Diagnostic de l'hypertension artérielle pulmonaire
WO2003038444A3 (fr) Biomarqueurs de reponse hepatique
EP0869174A3 (fr) Procédé pour clonage et production de l'endonucléase de restriction Spel
WO2005040107A3 (fr) Procedes pour fabriquer la simvastatine et leurs intermediaires
WO2001062784A3 (fr) Proteines
WO2003062443A3 (fr) Composes alcanes substitues et utilisations associees
WO2002039122A3 (fr) Compositions et methodes permettant l'identification, l'evaluation, la prevention et la therapie des maladies cardio-vasculaires
WO2005026392A3 (fr) Compositions, reactifs, et kits et procede de diagnostic, de controle et de traitement de l'obesite et/ou du diabete
WO2000014206A3 (fr) Cellulase mutante egiii, adn codant ces compositions d'egiii et leurs procedes de preparation
WO2005123913A3 (fr) Compositions d'enzymes thermostables modifiees de façon reversible, et methodes de production et d'utilisation desdites compositions
WO2003042357A3 (fr) Enzymes
WO2003016550A3 (fr) Compositions et procedes comprenant un acide nucleique temoin
WO2000050631A3 (fr) Compositions et methodes de controle de la modification de partenaires de liaison naturels
WO2004009786A3 (fr) Modulateurs de l'activation des leucocytes, compositions bic et leurs procedes d'utilisation
WO2003047421A3 (fr) Methodes et reactifs pour le diagnostic et le traitement du diabete
WO2003072729A3 (fr) Enzymes
WO2005115456A3 (fr) Procede de modulation du systeme endocrinien de reproduction par modulation de l'activite de tnf-$g(a)
WO2001014533A3 (fr) Proteine
WO2003031584A3 (fr) Reparation d'axone
WO2003093439A3 (fr) Enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP